 The purpose of this study is to assess the safety and efficacy of Ultrase MT20 compared to placebo for the correction of fat and protein malabsorption in participants with cystic fibrosis CF and exocrine pancreatic insufficiency EPI. This study is sponsored by Aptalis Pharma formerly Axcan. 